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Glioblastoma (GBM) is the most common and most malignant primary brain tumor. 
The highly invasive nature of GBM limits the outcome of standard therapy. The 
resistance to conventional therapy, including safe surgical resection, followed by 
radiotherapy (RT) and chemotherapy, leads to a poor median survival of 14.6 months 
after diagnosis. The highly immunosuppressive microenvironment and tumor 
heterogeneity make it difficult to treat GBM. Thus, new and more innovative 
treatment strategies are urgently needed to improve the poor prognosis of GBM 
patients. In this regard, several molecular targeted therapies have been developed and 
tested over the last two decades. Gene therapy is one of the new promising strategies 
that may improve patient outcome.  
Herpes simplex virus thymidine kinase gene (HSV-TK)/Ganciclovir (GCV) suicide 
gene therapy (SGT) converts a nontoxic prodrug into a cytotoxic drug that kills 
dividing tumor cells. It has been shown in earlier studies that the metabolized 
cytotoxic drug spreads to neighboring cells through gap junctions to execute the so-
called bystander effect (BE). This phenomenon is highly important for SGT as the 
transduction of 100% tumor cells in a given tumor is impossible, even with highly 
efficient viral vectors. While gap junction-mediated BE is highly characterized in the 
HSV-TK/GCV system, it is not clear if soluble factors such as apoptotic bodies 
(ApoBDs), microvesicles (MVs) and exosomes (exo) play any role in this process. 
In this project we investigated the potential involvement of these soluble cellular 
factors in the process of HSV-TK/GCV-mediated BE. We hypothesized that GCV 
treatment of tumor cells would increase the secretion of extracellular vesicles (EVs) 
and thus contribute to an increased BE. Two alternative mechanisms could contribute 
to this BE, either by loading of EVs with the HSV-TK.GFP protein or with GCV. 
Here, we focused on investigating the presence of the protein in EVs.  
In this present study, we used the human U87 glioma cell line to investigate the 
increase of EV-secretion following HSV-TK/GCV gene therapy, which could in 
theory contribute to BE. Our study showed successful secretion and harvest of EVs in 
this model system. We were also able to show EV secretion in the patient-derived 
glioblastoma P3 cell line cultured in serum-free neurobasal medium, which is more 
relevant to the clinical scenario. Most importantly, we showed for the first time the 
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presence of the TK.GFP protein in ApoBDs, MVs and exosomes derived from TK-
containing cells.  
In conclusion, our study highlights that the TK protein can be loaded in EVs secreted 
from TK-expressing cells. Thus, the transfer of the TK protein through EVs  might be 
an important contributor to the BE in SGT. In the future it will be important to 
investigate if also TK mRNA is transferred through EVs and then translated into 
active protein in the recipient cells and/or if transfer of phosphorylated GCV can 






























Cancer is referred to a group of diseases characterized by uncontrolled cell growth 
and proliferation [1].  In a seminal paper Hanahan and Weinberg proposed six key 
hallmarks of cancer namely: Evading growth supressors, activating invasion and 
metastasis, enabling replicative immortality, inducing angiogensis, resisting cell 
detah and sustaining prolifertaive signaling [2]. Self-sufficiency of growth signals 
and insensitivity to anti-growth signals leads to unregulated growth and 
accumulation of mutations. These acquired and inherited unfavorable 
abnormalities result in tumor formation. Metastasis, the process that refers to 
colonization of tumor cells  from the tissue of origin to a distant tissue, is the 
primary cause of cancer morbidity and mortality [3]. Although most tumors 
harbor genetic abnormalities in some common set of signalling pathways, 
tumorigenesis is very complex, and the underlying cellular and molecular 
pathways may vary within different cancer types [3]. Extensive research over the 
last decade has identified more biological processes associated with 
carcinogenesis. In line, Hanahan and Weinberg lately introduced two more 
enabling hallmarks; tumor promoting inflammation and genome instability [2].  
 
1.2 Brain cancer 
 
Tumors are classified into two main groups: benign or malignant tumors [4]. 
Neoplastic growth of cells in the brain or central nervous system (CNS) leads to 
tumor formation. When the origin of neoplastic growth is located inside the brain, 
the corresponding tumors are called primary brain tumors. When malignant 
tumors originate in other body parts and metastasize to the brain, the tumors are 
called secondary brain tumors. Most common sites of origin of secondary brain 
tumors are skin, colon, lungs or breast [5]. As the present work is based on 
primary brain tumors, this tumor class will be described in more detail. The most 
common form of primary brain tumors are collectively known as gliomas.  This 
assembly of tumors is based on the hypothesized cellular root of the individual 
entities- the glial cell [6]. The term glioma was coined by Dr. Rudolph Virchow in 











Figure 1.1. Pie chart showing the distribution of different gliomas by histological 
subtypes in the USA. Astrocytoma including Glioblastoma acount for ~ 75% of all gliomas. 
This distribution is from 2008-2012, n= 97.910. Figure is adopted from [8] 
 
Astrocytomas, account for 75% of all “nondiffuse” gliomas, and they are the most 
frequent and malignant representative. These subgroups are assigned with malignancy 
grade (WHO grade I, II, III or IV) based on the appearance/nonappearance of mitotic 
activity, microvascular proliferation and necrosis[9]                                                   
 
Classification of Astrocytoma  
- Grade I astrocytoma (Pilocytic astrocytoma): Benign and non-infiltrating 
tumor. It is characterized by slow growth rate without any nuclear atypia [10]. 
- Grade II astrocytoma (Low-grade/diffuse astrocytoma): Shows no sign of 
malignancy and express moderate nuclear atypia [11].  
- Grade III astrocytoma (Anaplastic astrocytoma): Characterized by nuclear 
atypia, lacking necrosis and increased cellularity [12].  
- Grade IV astrocytoma (Glioblastoma): The most malignant astrocytoma with 
presence of microvascular proliferation and necrosis.  
Grade I astrocytoma (low-grade) is most seen in children and young adults. The tumors 
are less clinically aggressive and often removed by surgery alone. Grade II-IV poses a 
difficulty for treatment and normally requires combination therapy that involves 
surgical resection of the tumor followed by temozolomide (TMZ) chemotherapy and 
radiotherapy [13].  
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1.3 Glioblastoma (GBM)  
 
GBM is the most common type of glioma. GBM patients have a median survival 
time of about 15 months after diagnosis making it one of the most aggressive 
cancers in humans [13]. The incididence rate of GBM is 2-3 new cases per 
100 000 people among adults in Europe and North America and it is slightly 
higher in men compared to women (1.26:1) [14]. GBM cases in children and 
infants are less frequent and although no morphological differences are observed 
compared to adult GBMs, pediatric GBMs have a completely different mutational 
profile [14]. Although GBM is sporadic, underlying rare genetic disorders such as 
Turcot syndrome, multiple endocrine neoplasia type IIA, tuberous sclerosis, 
neurofibromatosis type-1 (NF1) and Li Fraumeni syndrome (LFS) are associated 
with GBM incidents [14, 15]. Some epidemiology studies also support the link 
between traumatic brain injury and subsequent GBM formation [16, 17]. Higher 
incidence of GBM in Caucasians and especially people living close to industrial 
areas have also been reported [18]. Certain viruses, such as human 
cytomegalovirus (HCMV) have also been reported to have an impact on GBM 
development [14]. Pesticides, polycyclic aromatic compounds and other solvents 
that are considered as dangerous chemicals can increase the likelihood for 
developing GBM, as well as ionizing radiation [14, 18]. Genetically and 
phenotypically GBM consist of heterogenous group of tumors which are 
histologically indistinguishable. Although no morphological differences have been 
observed, GBM is divided into two subgroups due to different genetic 
mechanisms and pathways of tumorigenesis: primary GBM and secondary GBM 
[19]. Primary GBM develop rapidly de novo in elderly people without any signs 
of a lower grade precursor lesion and it accounts for ~90% of all GBMs. In 
contrast, secondary GBM have a delayed development through progression from 
low-grade astrocytoma or anaplastic astrocytoma. Secondary GBM has a higher 























Figure 1.2 Primary and Secondary GBMs. Primary GBM develop rapidly de novo and 
accounts for ~ 90% of all gliomas. Secondary GBM have a delayed development through 
progression from low-grade astrocytoma and accounts for the minority of all GBM cases. 
Figure is adapted from [20].  
 
Primary GBM is characterized by gain of chromosome 7 and by 
amplification/overexpression and mutations of Epidermal Growth Factor Receptor 
(EGFR). Deletion of tumor suppressor phosphatase and tension homolog on 
chromosome 10 (PTEN) and 16q [19, 20] are also frequently observed. PTEN 
functions as a cellular phosphatase and in case of inactivating mutation results in a 
constitutively activated Phosphatidylinositol 3.4.5 biphosphate kinase (PI3K/Akt) 
pathway. Isocitrate Dehydrogenase I (IDHI) is an enzyme that has an important role 
in energy metabolism and mutation in this component is related to the occurrence of 
glioma [21]. Although, IDH1 mutations are rarely seen in primary GBM (<5%), they 
are represented in a much higher degree in secondary GBM (>80%) and also low 
grade gliomas [22]. Loss of heterozygosity (LOH) on chromosome arm 10q is the 
most frequent genetic alteration seen in both primary and secondary GBMs.  
Based on gene expression and mRNA profiling GBM is subclassified into proneural 
(PN), mesenchymal (MES) and classical GBMs, each with different pattern of disease 
and survival outcomes [23] . The PN subtype is associated with IDH1 mutations, 
Platelet-Derived Growth factor receptor (PDGFR) amplification/mutation and Tumor 
protein 53 (TP53) [24], while EGFR amplification is characteristic for the classical 
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subtype. The mesenchymal subtype often harbours NF1 mutations and shows strong 
activation of the Nuclear factor-κB (NF- κB) pathway [23]. NF- κB consists of a 
family of transcription factors that is highly involved in inflammation, survival, 
differentiation, immunity and cell proliferation [25]. Thus, it is not surprising that 
mesenchymal GBM consist of an inflammatory tumor microenvironment which is 
dominated by immunosuppressive macrophages/microglia. The mesenchymal subtype 
is also associated with the poorest prognosis and the worst patient outcome [23].  
 
1.4 Histopathological features of GBM  
 
As the name “multiforme” suggest, the histopathological features of GBM are many 
and various in its appearance. As described previously (section 1.2), GBM is 
composed of a pleomorphic tumor cell population showing nuclear atypia and mitotic 
activity. In addition, microvascular proliferation and necrotic areas are specific for 
GBMs and are usually not observed in low grade gliomas. The formation of 
pseudopalisading necrotic regions is a result of cells escaping the hypoxic and 
necrotic areas which are characterized by oxygen and nutrition depletion [26, 27]. 
Pseudopalisading cells show increased expression of hypoxia-inducible factor (HIF) 
which leads to secretion of the HIF target gene vascular endothelial growth factor 
(VEGF) at high levels. Together with Interleukin-8 (IL-8), this reaction stimulates an 
excessive angiogenic response.  
 
Figure 1.3. Palisading of tumor cells and microvascular proliferation around necrosis. 
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1.5 Current treatments for GBM  
 
As described earlier, GBM is a primary brain tumor with a remarkably poor 
prognosis. 1/3 of the patients dies of the disease within a year after diagnosis. The 
standard therapy for GBM treatment is maximal neurosurgical resection followed by 
radiotherapy and adjuvant concomitant chemotherapy with temozolomide (TMZ) 
[14]. Complete resection of the tumor is not feasible due to its extreme invasive nature 
and capability to infiltrate surrounding healthy brain tissue. Surgery is therefore 
followed by radiotherapy (RT) to eliminate the remaining tumor cells. As a result of 
radiation, the DNA damage response pathway is induced in the proliferative tumor 
cells [30, 31].  Until 2005 the standard treatment of care for GBM was resection of the 
tumor followed by only RT. However, Stupp et al. showed that the combination of RT 
with concurrent TMZ chemotherapy was more effective than RT alone. Patients 
receiving both RT and TMZ had an increased median survival of 14.6 months 
compared to 12.1 months with RT only [30]. TMZ is an orally-given alkylating anti-
cancer agent that functions by breaking DNA-double strands, subsequently causing 
cell cycle arrest and ultimately cell death [32].  The success of TMZ treatment is 
affected by the methylation of O6-Methylguanine DNA methyltransferase (MGMT), 
which is a DNA repair enzyme.  A methylated MGMT enhances DNA damage in 
tumor cells upon TMZ treatment that results in apoptosis and cytotoxicity and thus 
improves patient outcome [32, 33]. Despite the improvement of standard treatment, 
most GBM patients experience recurrences within 6 months following TMZ 
discontinuation [34]. Additionally, tumor cells can become resistant to the effect of 
TMZ.  
Thus, new and more innovative treatment strategies are urgently needed to improve 
the poor prognosis of GBM patients. To improve the treatment modality further, over 
the last two decades several molecular targeted therapies have been developed and 
tested. Figure 1.4 shows the overview of the therapies that fell short of expectation in 
terms of therapeutic efficacy [35].  Gene therapy is one of the new promising 












       Figure 1.4 Traditional targeted therapy vs. Novel therapeutic strategies. Traditional 
therapy hindered by BBB and the heterogenic nature of tumor cells. Novel therapeutic 
approaches are promising for the future. Figure is adapted from  [36] 
 
1.6 Gene therapy  
 
Scientist have been working for decades on multiple ways to manipulate the human 
genome since the recognition of the gene as the basic unit of heredity. Gene therapy is 
defined as strategies involving modification of genes or replacement of abnormal or 
altered genes with healthy ones to prevent, treat or cure a disease or a medical 
condition [37]. Initially, gene therapy was conceived to treat genetic diseases by 
substituting one single mutated gene through delivery of a functional version of the 
gene. This idea was further developed to include the delivery of engineered genetic 
material to target cancer cells by killing or enhance the immune response against them 
[38]. Applying gene therapy for cancer has been challenging as tumors develop 
through multiple known and unknown genetic abnormalities and it requires 
replacement of several genes. Strategies for cancer, gliomas in particular, has been in 
development for several decades, and major approaches have been employed for gene 
therapy of GBM. This includes delivery of suicide genes, cytokine genes, tumor-
suppressor genes [38, 39]. Different carriers of the genetic material have been 
developed. Viruses are evolved as effective vehicles for horizontal gene transfer as 
they efficiently target mammalian cells. Thus, viruses are the preferred type of vector 
for gene therapy approaches.  Other agents such as stem cells, nanoparticles and 
20 
 
liposomes have also been developed. Cellular carriers such as neural, mesenchymal or 
embryonic stem cells can additionally be used due to their competence to spread 
within the tumor tissue and migrate to distant tumor areas [40].  
Different approaches for gene therapy have been developed for GBM treatment.  
Major approaches used for gene therapy against GBM include suicide gene therapy, 
oncolytic gene therapy, cytokine mediated gene therapy, and tumor suppressor gene 

















Figure 1.5 Different Gene therapy approaches of GBM. A) Suicide genes: Prodrug is 
converted into a cytotxic drug upon delivery of the suicide gene and kills recipeient cells and 
surrounding tumor cells. B) Immune activation: Immune cells attracted to tumor cells upon 
delivery of cytokine genes. C) Oncolysis: Conditionally-replicating oncolytic viruses lyse the 
tumor cellsupon infection and replication. D) Reprogramming: Tumor cells are 
reprogrammed by delivery of a functional copy of a tumor supressor gene that induce celle 




1.6.1 Suicide gene therapy and HSV-TK/GCV system 
 
SGT is a therapeutic strategy that is based on the conversion of a prodrug into a toxic 
drug by transgenes [42]. A prodrug is an inactive compound that after administration 
is metabolized into a pharmacologically active drug [43]. This system involves the 
transduction of cancer cells with a recombinant genetic segment (known as the suicide 
gene) encoding an enzyme. That particular enzyme is  responsible for catalyzing the 
non-toxic prodrug into a cytotoxic drug [44].  
Various suicide gene therapy systems have been developed and the two major systems 
currently being pursued are the herpes simplex virus thymidine kinase gene (HSV-
TK) with ganciclovir (GCV) as prodrug and cytosine deaminase (CD) of Escherichia 
coli with  non-toxic 5-fluorcytosine (5-FC) as prodrug [43]. The HSV-TK gene 
metabolizes GCV to ganciclovir monophosphate (GCV-MP). GCV-MP is further 
phosphorylated into the cytotoxic ganciclovir-trisphosphate (GCV-TP) by the action 
of different cellular kinases [45]. Cellular enzymes are presented in all cells, but 
suicide enzymes are selectively transduced/activated in the tumor cells via gene 
therapy. GCV-TP acts as a nucleoside analog and gets incorporated into the DNA of 
dividing cells. This results in DNA damage, subsequent cell cycle arrest followed by 
apoptosis. Normal dividing cells are not affected by the toxicity as the analogs are not 
efficiently recognized by the wild type enzymes [46].  
Several tumor models revealed powerful killing by the HSV-TK/GCV system. 
However, the killing efficacy is increased with the recombinant version of HSV-TK, 
termed TK.007, when compared to wild type HSV-TK [47, 48]. In order to obtain 
positive therapeutic outcome, the selection of the viral vector for gene delivery is 
essential. Lentiviral vectors are competent of integrating into the genome of both 
dividing and non-dividing cells, which makes them appealing in brain tumor gene 
therapy  
 
1.7 Bystander effect  
 
The efficiency of SGT largely depends on a phenomenon called bystander effect (BE) 
whereby the transduced cancer cells transfer the already-metabolized drug to the 
untransduced cells. As a result, the untransduced cancer cells also undergo cell death 
[49]. Thus, a potent bystander effect is crucial to induce therapeutic efficacy, because 
22 
 
gene transfer remains to be a limiting factor for suicide gene therapy even with highly 
optimized vector systems [50]. Thus, in principle, only a fraction of tumor cells need 
to express HSV-TK to obtain a large killing effect after GCV administration [51]. 
GCV-TP, the final toxic metabolite is not able to diffuse through cellular membrane 
to neighboring cells to execute the BE. Initially, it was suggested that the BE was 
promoted through a mechanism involving cell-to-cell contact. Later, it was indicated 
that phosphorylated GCV was actively transported through gap junctional intracellular 
communication from TK positive cells to negative cells [49].  
 
 
Figure 1.6: Suicide Gene Therapy. Bystander effect is executed on neighboring tumor cells 
when the non-toxic prodrug is metabolized into toxic drug upon suicide gene delivery into the 
tumor. Figure is adapted from [52].   
 
Gap junctions are a cluster of channels composed of membrane proteins that allows 
for intracellular communication between adjacent cells via diffusion of ions and small 
molecules [53, 54]. Six connexin proteins together oligomerize into a connexon at the 
cell surface. Connected connexons of two adjacent cells ensure for gap junction-
mediated intracellular communication [55]. The primary mechanism of the BE in 
vitro has been attributed to connexin 43-mediated gap junction communication, 
however the expression of connexins in vivo is more heterogenous which might affect 
the efficiency of HSV-TK/GCV therapy.  
While gap junction-mediated BE is highly characterized in the HSV-TK/GCV system, 
it is not properly clear if vesicles secreted from the tumor cells such as apoptotic 
bodies (ApoBDs), microvesicles (MVs)  and exosomes (Exo) play any role in this 
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process. ApoBD-mediated BE was reported in murine sarcoma cells [56] however the 
authors did not investigate if it was due to transfer of the TK mRNA, TK-protein or 
the toxic drug. It is also not known if GBM cells are also amenable to such 
mechanism. In this context, the mechanism of CD/5FC-associated BE has been 
studied in detail which has shown that the EVs play important role in CD/5FC BE. 
Altaenrova et al. reported that exosomes produced by CD-expressing mesenchymal 
stem cells (MSCs) contain the mRNA transcript of the suicide gene that can exert 
cytotoxicity in recipient cells [57]. It is not known if the mRNA or protein of TK can 
similarly be loaded into EVs. There is also a possibility that the toxic drug could be 
loaded into EVs and thereby mediate the BE in recipient cells, however the issue has 
not been investigated so far. 
 
1.8 Extracellular vesicles and their role on intracellular signaling  
 
In the last decades, the scientific interest describing the function of extracellular 
vesicles (EVs) and how they can be used in therapeutic applications hasexpanded 
substantially. Exosomes (Exos), microvesicles (MVs), apoptotic bodies (ApoBDs), 
microparticles, oncosomes and ectosomes are all different types of membrane 
structures released by cells that are commonly termed EVs [58]. These membrane-
contained vesicles are released by both prokaryotes and eukaryotes. EVs are 
mediators of intercellular communication between cells due to their ability to carry 
several biomolecules and transfer proteins, lipids, nucleic acids and different types of 
RNA (mRNA, miRNA and other non-coding RNA), in an endocrine, paracrine and 
autocrine fashion [59]. Thus, EVs influence different physiological and pathological 
functions of both recipient and parental cells. Consequently, EVs are involved in 
many processes/diseases such as neuronal function, immune responses, 
neurogenerative diseases and cancer [60]. The content of the EVs and their biological 
functions depends on the cell of origin [61].  
In 2014, The International Society for Extracellular Vesicles (ISEV) composed of 
researchers worldwide proposed guidelines with Minimal Information for Studies of 
Extracellular Vesicles (MISEV2014), which was again updated in 2018 





1.8.1 Exosomes, Microvesicles and Apoptotic bodies  
 
EVs, the general term for all secreted vesicles such as exosomes, microvesicles and 
apoptotic bodies, are found in body fluids such as urine and blood which makes them 
ideal carriers of biomarkers. Previously, they were considered as cellular trash due to 
their invisibility, small size, and lack of entity [59]. Exosomes are released upon 
fusion of multi-vesicular bodies (MVBs) with the plasma membrane, and are formed 
in the endosomal network in an inward budding process [58]. Exosomes are the 
smallest subtype among the EVs with a size ranging from 30-100 nm and cup-shaped 
in apperance under the electron microscope (EM) [60].  In contrast, microvesicles are 
formed in a process of outward budding and fission of the plasma membrane. MVs 
tend to be bigger in size ranging from 50 nm-1μm and are primarily distinguished 
from exosomes by its mode of biogenesis [63]. When cells undergo programmed cell 
death, apoptosis, the cytoskeleton breaks up and causes the membrane to bulge 
outward. Blebs of cells containing dying parts are released as apoptotic bodies in a 
multistep process in the extracellular space. This is a major mechanism among normal 
and cancerous cells. ApoBDs are generally larger in size compared to other EVs, 
ranging from 500-2000 nm [64]. After release, ApoBDs are removed via phagocytosis 
by macrophages in vivo. This is mediated by an interaction between the macrophages 
and surface proteins on the apoptotic membrane [63, 65].  
Surface markers, method of isolation, size and the source of origin are the criteria that 
must be met to subclassify EVs into defined vesicles.  However, circulating vesicles 
in fluids are prone to contain both exosomes and MVs, and unfortunately with 
purification methods available per today, it is still difficult to fully discriminate 











Figure 1.7 Exosomes, Microvesicles and Apoptotic bodies. Exosomes are released upon 
fusion of multi-vesicular bodies (MVBs) with the plasma membrane, while microvesicles are 
formed in a process of outward budding and fission of the plasma membrane. When cells 
apoptosis, the cytoskeleton breaks up and blebs of cells containing dying parts are released as 
apoptotic bodies. Figure adapted from [65] 
 
1.8.2 Involvement of EVs in GBM  
 
In the recent years research has clearly shown that GBM cells secrete EVs which are 
competent of escaping the tumor microenvironment and delivering genetic information 
to recipient cells that inflect their behavior[61] . GBM-secreted EVs have self-
promoting features such as stimulating proliferation and angiogenesis in a pro-
tumorigenic way. EVs secreted from tumor-cells can also engineer their surroundings 
in a benficial manner to tolerate tumor growth and invasion [67]. Skog et al., showed 
that GBM-secreted EVs from U87 glioma cells can stimulate proliferation of recipient 
cells. As demonstrated in additional studies, tumor-derived EVs support several 
hallmarks of cancer and better understanding of them will acknowledge novel 
diagnostic and therapeutic targets [61].  
 
1.8.3 Methods for isolation of EVs  
 
According to ISEV, a complete purification of EVs is not possible. There is no 
standardized single separation method and thus the choice of approach depends on the 
experimental question and final use of EVs [62]. Primary EV separation technique is 
ultracentrifugation-based, but alternative methods such as density gradients, 
immunoprecipitation, filtration and size exclusion chromatography and 
immunoisolation are also used [58]. Ultracentrifugation is the gold standard for 
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isolation today involving repeated centrifugation steps which results in larger and 
more dense particles sedimenting out first [30, 62].  
 
1.8.4 EVs marker proteins  
 
Isolated EVs are typically characterized by immunoblot analysis to demonstrate the 
presence of markers proteins or by transmission electron microscopy (TEM) to reveal 
a cup-shaped morphology [68].  Enrichment of these proteins in both exosomes and 
MVs is known to be highly dependent on the parental cell type [69]. Exosomes are 
enriched with endosome-associated proteins such as Annexins and flotilin due to their 
endocytic route. Other proteins such as Alix, TSG101, heat shock proteins, major 
histocompatibility complex (MHC) class I and MHC class II complexes and the 
tetraspanins  CD9, CD81 and CD63 are often termed “exosomal markers” [70]. The 
abundance of tetrapanins and other proteins associated with the plasma membrane are 
commonly found in exosomes, and more enriched in these vesicles compared to cell 
lysates [70, 71]. Tetraspanins were suggested as specific markers for exosomes until 
studies revealed that these proteins could also be identified in MVs [72, 73]. MVs 
mainly contain cytosolic and plasma membrane associated proteins, such as 
tetraspanins. Proteins involved in post translational modifications, integrins, selectins 
and CD40 are all identified in MVs, however, the three latter are the main MV protein 
markers [66]. Nonetheless, specific markers that distinguish between MVs and 
exosomes have not yet been identified [70, 74]. In contrast to exosomes and MVs, 
ApoBDs contains small amounts of glycosylated proteins, chromatin and intact 
organelles. Annexin V, histones, and C3B and are used as molecular markers in larger 
EVs such as ApoBDs in some cell types [63, 75]. As suggested by ISEV, a set of 
marker proteins should be analyzed and either be enriched or absent from different 












The present thesis aims to explore the potential ability of extracellular vesicles such as 
exosomes, microvesicles and apoptotic bodies to increase the bystander effect of 
glioblastoma suicide gene therapy. .  As explained in the introduction, the efficiency 
of SGT largely depends on the phenomenon called bystander effect (BE) whereby 
transduced cells transfer the already-metabolized toxic drug to the un-transduced 
tumor cells. As a result, the un-treated cells also undergo apoptosis. While gap 
junction-mediated BE is highly characterized in HSV-TK/GCV system, it is not 
properly clear if soluble factors such as apoptotic bodies, microvesicles and exosomes 
play any role in this process. In this project we are investigating the potential 
involvement of these soluble cellular factors in the process of HSV-TK/GCV-
mediated BE. Our objectives are as follows:  
- to analyze the HSV-TK/GCV-mediated cytotoxici effect on the secretion of 
extracellular vesicles  
- to analyze the possible loading of HSV-TK.GFP protein in the extracellular 
vesicles and  
potential transfer thereof to other cells 
- to analyze the cytotoxic effect following potential transfer of extracellular 














3. Materials and Methods 
 
3.1 Cell culture 
3.1.1 Media preparation  
 
Dulbecco’s Modified Eagle’s Medium (DMEM): DMEM (Sigma-Aldrich Inc., St. 
Louis, MO, USA) was supplemented with 10% heat inactivated Fetal bovine serum 
(FBS) (Thermo Fischer Scientific, Waltham, MA, USA), 0.02% Plasmocin 
(Invitrogen, Toulouse, France),  2% (v/v) Penicillin-Streptomycin (BioWhittaker, 
Verviers, Belgium), 2% (v/v) L-glutamine (BioWhittaker), 3.2% non-essential amino 
acids (NEAA) (13-114E, Lonza, Walkersville MD USA). DMEM with all the 
supplements mentioned in this section is stated as complete DMEM throughout the 
thesis.  
Exosome Depleted Fetal Bovine Serum (FBS) Medium: 
Exosome depleted FBS was obtained by centrifuging (Beckman Coulter Optima LE- 
80 K ultracentrifuge)  regular FBS in Quick-Seal Polypropylene centrifuge tubes 
(Beckman Coulter, Inc. 250 S, Kraemer Blvd. Brea, CA 92821, USA) for 18 hours at 
40 000 rpm (179200 gmax) and 4°C using a Ti70 rotor (Type 70 Ti Fixed-Angle 
Titanium Rotor, Beckman Coulter, USA). Only the supernatant was retained and 
used. Further, the centrifuged exosome depleted FBS was filtered with 0.2 µm filter  
(Life Sciences, Acrodisc® Syringe filter) before 10 % was added to DMEM. The medium was 
alliquoted in 50 mL Falcon tubes and kept at – 20 °C.  
Exosome Depleted Fetal Bovine Serum (FBS) DMEM medium: DMEM was 
supplemented with 10% exosome depleted FBS, 0.02% Plasmocin, 2% (v/v) 
Penicillin-Streptomycin, 2% (v/v) L-glutamine, and 3.2% NEAA. DMEM with all the 
supplements mentioned in this section is stated as exosome depleted DMEM 
throughout the thesis.  
Dulbecco’s Modified Eagle’s Medium (DMEM) with Ganciclovir (GCV): 
Complete DMEM supplemented with GCV (G2536, Sigma-Aldrich) to a final 
concentration of 25 µM.  
Exosome Depleted Fetal Bovine Serum (FBS) DMEM medium with GCV: 




Neurobasal Medium (NBM): NBM was supplemented with 1% (v/v) Penicilin-
Streptomycin, 1% (v/v) L-Glutamine, 2% (v/v) B27 Supplement (50X) ( 
GibcoTM,Thermo Fisher Scientific, Waltham,MA,USA), , 0.1% Heparin LEO 5000 
IE/ml (Vitusapotek), 20ng/ml Fibroblast Growth Factor-basic (bFGF) (100-18B, 
PeproTech®,Germany). It is stated as complete NBM throughout this thesis.  
Cell freezing media: Complete DMEM was supplemented with 10% v/v Dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich, Steinheim, Germany) and 10% v/v FBS.  
 
3.1.2 Drug preparation  
Ganciclovir (GCV):  
Table 3.1: Information about GCV, modified from the Sigma Aldrich webpage [76]   
Synonym: 9-(1,3-Dihydroxy-2-propoxymethyl) guanine;2¢-Nor-2¢-
deoxyguanosine; 2¢-NDG; BIOLF-62; DHPG; BW-759U 
Application: GCV, a nucleoside analog that causes inhibition of viral DNA 
polymerase  
CAS Number: 82410-32-0 
Molecular weight: 255.23 (Da) 
Molecular formula: C9H13N5O4 
Appearance: Powder  
Physical state: Solid  
Solubility: Soluble at 10 mg/mL in 0.1. N HCl  
Storage:  2-8 °C 
Table 3.1 – displays important information about the prodrug used in this thesis, GCV 
(G2536, Sigma-Aldrich). The drug was received as powder and dissolved in complete 
DMEM to a final concentration of 3mM, aliquoted in 2.0 mL Eppendorf tubes 
(Eppendorf AG, Hamburg, Germany) and stored at -20 °C. New aliquot was used for 
each experiment, and stock solutions were thawed at room temperature (25 °C), and 







3.1.3 Cell Lines  
U87: U87, formally known as U-87 MG (Uppsala 87 Malignant Glioma) is a patient-
derived primary GBM cell line, which was originally established at Uppsala 
University . This is a high grade glioma cell line that is commonly used in 
glioblastoma research. The cells are adherent and grows in monolayer. They exhibit 
epithelial morphology and were maintained in either complete or exosomes depleted 
DMEM until they reach the desired confluency.  
P3: P3 is a patient-derived primary GBM cell line, which was established at 
Haukeland University Hospital, Bergen, Norway, generated from surgical resections. 
The cells are adherent and grows in monolayer, and they were maintained in complete 
NBM medium until they reached the desired confluency.  
U87.TK.GFP and P3.TK.GFP: U87 cells were previously transduced with HSV-
TK. 007 construct in the lab of Prof. Hrvoje Miletic.  The lentiviral construct has 
previously been described in section 1.6.1 [77]. HSV.TK.007 transduced U87 and P3 
cells were stated as U87.TK and P3.TK, respectively, throughout this thesis.  
 
3.1.4 Sub-culturing and Passaging  
Cell lines were kept in T175 culture flask (Nunc, Roskilde, Denmark) and maintained 
in a humidified incubator (Thermo Forma, Steri Cycle CO2 Incubator, 301210-634, 
Ohio, USA) at 37 °C and 5% CO2. Cell lines were subcultured at 75-80% confluency. 
Dulbecco’s Phosphate buffer saline (PBS) (10X) (D1408, Sigma Aldrich, St Louis, 
Missouri, USA) diluted in autoclaved Milli-Q water (QGARD00R1, Millipore, 
France) to 1X working concentration was used as washing buffer. Nikon Eclipse 
TS100 (Nikon Corporation, Tokyo, Japan) inverted microscope was used to daily 
monitor the cells. All cell culture work was carried out in sterile condition under 
laminar flow bench (SANYO Electric Co, Osaka, Japan). The hood and equipment 
going in was sterilized with 70% ethanol before and after use.  
U87, U87.TK.GFP, P3, P3.TK.GFP: Cell culture media was aspired, and the cell 
flasks were washed twice with 1x PBS. U87 cells were detached using Trypsin-EDTA 
(BioWhittaker) and incubated at 37 °C for 5 min. Trypsin process was neutralized 
with either complete DMEM or exosome depleted DMEM. P3 cells were deatched 
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from the buttom by scraping the surface with a cell scraper (VWR®, Pennsylvania, 
USA) and transferred to 15 ml tubes (Sarsted, Nümbrecht, Germany). The old media 
was removed by centrifugation at 300 g for 5 min, follwed by washing with 1x PBS. 
Both cell lines were resuspended in their respective media until single cell suspension 
was obtained. Resuspended cells were added to fresh flasks or counting. All cells 
were used for 15 passages post-thawing, one passage being considered as one 
trypsinization.  
 
3.1.5 Cell counting  
The cells were counted before in vitro experiments were performed. 100 µl of cell 
suspension was diluted in 400 µl Trypan blue dye (Life Technologies, OR, US) which 
is useful to differentiate dead and live cells based on the cell’s ability to take up or 
exclude the dye. Live cells do not take up Trypan blue dye. 10 µl of diluted single 
cell/Trypan blue dye suspension was loaded to each chamber of hemocytometer 
(8100203, Neubauer, Hirschmann Laborgeräte GmbH & Co, Eberstadt, Germany) and 
covered with cover glass (Menzel-Gläser, Thermo Scientific). Hemocytometer 
consists of two identical chambers and each one has nine big squares of 1 mm2 that 
are subdivided in three parallel lines with depth of 0.1 mm. Eight of the big squares 
have 16 squares whereas 1 big square in the center has 25 small squares. From each 
compartment, cells were counted from 4 big squares and the average was calculated. 
Cell concentration was calculated by following formula: 
 
Number of cells/ml= 
𝐓𝐨𝐭𝐚𝐥 𝐜𝐞𝐥𝐥 𝐜𝐨𝐮𝐧𝐭 𝐱 (𝐃𝐢𝐥𝐮𝐭𝐢𝐨𝐧 𝐅𝐚𝐜𝐭𝐨𝐫 𝐱 𝟏𝟎𝟒)
𝐍𝐮𝐦𝐛𝐞𝐫 𝐨𝐟 𝐬𝐪𝐮𝐚𝐫𝐞𝐬 𝐜𝐨𝐮𝐧𝐭𝐞𝐝
∗ 𝟓 𝐭𝐫𝐲𝐩𝐚𝐧 𝐛𝐥𝐮𝐞 𝐝𝐢𝐥𝐥𝐮𝐭𝐢𝐨𝐧 𝐟𝐚𝐜𝐭𝐨𝐫 
 
Figure 3.1 Hematocytometer. Left: Hematocytomter looked from the top. Right: Chamber 
of hematocytometer with 4 big squares. Cells presented on the dot lines were not counted. 




3.1.6 Thawing and cryopreservation of cells  
Cells were thawed by hand and immediately pipetted into a T75 cm2 flask containing 
15 mL of pre-warmed required media and resuspended gently prior to incubation at 37 
°C, 5 % CO2 and 100 % humidity. In order to remove remnants from freezing media, 
the cell culture media was replaced with fresh media after overnight incubation.  
The cells were frozen down when a T175 cm2 flask was 70-80 % confluent and after 
10-20 passages in cryopreservation. After single cell suspension was obtain as 
described in section 3.1.3, cells were transferred to a 15 mL Falcon tube (Thermo 
Scientific, NY, USA). The cell solution was centrifuged at 300 g for 5 minutes, the 
supernatant was removed, and the cell pellet was resuspended in cold freezing 
medium. 1.0 mL aliquots of cells were frozen in cryotubes (Nunc, Roskilde, 
Denmark) at -80°C in a Mr. Frosty™ Freezing Container (C1562, Sigma-Aldrich, 
Steinheim, Germany) overnight to provide a gradual temperature decrease. The next 
day, the cryotubes were transferred to liquid nitrogen tank for long time storage.  
 
3.2 Isolation of EVs by ultracentrifugation  
Prior to isolation of the EVs, the cell lines U87 and U87.TK.GFP were seeded in 
T175 cm2 at a concentration of 15.0x106 cells/35 mL in each flask. The cells were 
allowed to adhere for 24 hrs. before treating with condition media in the presence or 
absence of 25 µ M GCV. The day of isolation, the condition media was transferred 
directly from the flasks to 50 mL Falcon tubes. As negative controls, medium without 
drug for each cell line was used.  
The ultracentrifugation is a multi-step process, where the falcon tubes containing 
media were initially placed in a low speed spin centrifuge (Eppendorf Centrifuge 
5810 R (Sigma-Aldrich, Steinheim, Germany). In the first step, dead cells and other 
remnants were eliminated by centrifuging at 300 x g for 5 minutes. In order to collect 
apoptotic bodies, the supernatant from each falcon tube were transferred to clean 
tubes and spin down at 2000 x g for 20 minutes and 4 °C. Supernatant was transferred 
to quick seal centrifuge tubes through a syringe (50 mL, BD Luer-Lok syringe, Spain) 
to further harvest microvesicles, while pellet containing apoptotic bodies were put on 
ice. The centrifuge tubes were properly sealed using a sealing kit (Beckman Coulterm 
Cordless Tube Topper, Model: 7700, USA),  placed in a fixed angle centrifuge rotor 
(Type 70 Ti Fixed-Angle Titanium Rotor, Beckman Coulter, USA) and further 
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installed in the  Beckman Coulter ultracentrifuge. The samples were centrifuged for 
22 minutes at 15 000 rpm (25200 gmax)  and 4 °C. Supernatant was removed from the 
tubes using a syringe and transferred to clean centrifuge tubes in order to collect 
exosomes from the cell condition media. The pellet containing microvesicles were put 
on ice. A final high-speed spin was performed at 40 000 rpm (179200 gmax ) for 3 hrs. 
and 4 °C. The supernatant was discarded, and pellet containing exosomes saved on 
ice.  
The different EVs pellet were resuspended in filtered 1X PBS, transferred to Eppendorf 
tubes, and stored at -80 °C for further characterization and analysis.  
 
3.3 Western Immunoblotting  
Table 3.2- Reagents used for lysing the cells and EVs  
Reagents Name Composition     
1X PBS 10 Phospho-buffered saline in MilliQ  H2O 
RIPA Buffer  Radradioimmunoassay precipitation buffer  
Protease+Phophatase Inhibitors  
 
1 tablet protease inhibitors + 1 tablet phosphatase inhibitors in 
1mL RIPA Buffer 
 
Table 3.3- Reagents used for gel casting for SDS-PAGE.  




12%  Stacking Supplier  
dH2O 1.6 1.4  
30% acrylamide and bis-
acrylamide solution 2.0 0.33 A3699, Sigma-Aldrich, UK 
1.5M Tris pH 8.8 1.3 
 
-  
1.0M Tris pH 6.8 - 
 
0.25  
10% Sodium Dodecyl 
Polyacrylamide (SDS) 0.05 0.02  
10% Ammonium Persulfate (APS) 0.05 0.02 
A3678, Sigma-Aldrich, St Louis, 
Missouri, USA 






Table 3.4- Reagents used for running, transfer and blotting of SDS-PAGE.  
Reagents Name Composition              
 
Supplier  




1X Tris-Glycine transfer 
buffer 
BioRad 10X TG buffer + 20% 
methanol in dH2O 
 
Ponceau stain 0.1% Ponceau S in 5% Acetic Acid 
P3504, Sigma-Aldrich, St. 
Louis, Missouri USA 
5% blocking buffer 




0.02 M Tris-HCl (pH 7.5), 0.15 M 
NaCl and 0.1% Tween 20 
 
1X TBS 
Tris-Buffered Saline (0.2 M Tris-HCl 
(pH 7.5), 1.5 M NaCl) in dH2O 
 
 
To characterize and confirm successful harvest, the EVs from U87 and U87.TK 
+GCV/control were subjected to western immunoblotting. Cell lysates s were also 
included. After condition media was removed in order to collect the EVs, the adherent 
cells were washed with cold PBS, trypsiniezed, and counted in order to indicate % 
dead cells at the time of harvest. Following, transferred to 15 mL tubes and 
centrifuged at 3000 rpm for 5 minutes at 4°C.  
 
3.3.1 Protein concentration determination  
The cell pellet and isolated EVs were lysed by using Radioimmunoassay precipitation 
buffer, RIPA, supplemented with 10% protease (04693124001, Roche, Manheim, 
Germany) and phosphatase (04906845001, Roche, Indianapolis, USA) inhibitors. The 
protein concentration in each EV and lysate was determined using Pierce™ BCA 
Protein Assay Kit (Pierce Biotechnology, Rockford, lL, USA). With the relative 
absorbance measured with Direct Detect® Spectrometer (DDHW00010-WW, Merck 
Millipore, USA), we could make a calibration curve to determine the concentration of 
each sample.  
 
3.3.2 Gel Casting, Sample Preparation, SDS-PAGE, antibody incubation and 
protein detection  
12% Tris-Glycine Sodium Dodecyl Sulfate (SDS)-polyacrylamide gels were freshly 
casted before each western blot accordance to table __ in use of Mini-PROTEAN® 
Tetra Hand Cast System (Bio-Rad, Hercules, California, USA).  Samples were thawed 
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on ice with 25 µg total protein of each sample mixed with 5x Loading buffer (along 
with reducing agent and beta mercaptoethanol) and Milli-Q water was added until the 
desired volume was reached. The cell lysate mixture and the EVs mixture were then 
heated for 10 minutes at 70°C and 5 minutes at 95 °C respectively and spin down 
before loading on the gel. Precision Plus Protein Western C Standards (L001652A, 
USA) was used as protein marker size and loaded onto the first well of the gel. Equal 
amount of each samples were added to the remaining wells. Gels were run at 80 V 
(Bio-Rad Electrophoresis Power Supplier) for 30 min for protein stacking, and then at 
100 V for protein separation, in an electrophoresis chamber (BioRad, USA) filled 
with premade Tris-glycine running buffer. SDS-PAGE is a technique that allows 
separation of proteins based on their molecular weight. SDS is an anionic detergent 
used to denature proteins and it provides with an overall negative charge. In 
application of electric field, the smallest proteins migrate faster than the larger ones 
towards positive pole.  
Proteins separated on gel were transferred onto 0.2 µM pore nitrocellulose membranes 
(Bio-Rad laboratories AB, Oslo, Norway) by using the BioRad Mini Trans-Blot® 
transfer system. Blotting sponges, filter papers and the membrane were soaked in 
chilled Tris-Glycine transfer buffer and assembled (Figure 3.2) a small rolling pin was 
used to remove the air bubbles between the layers. Chamber filled with transfer buffer 
was placed on ice and the electrophoresis was run at 45 V for 90 min in use of 






Figure 3.2 Immunoblot sandwich. Correct way to asseble the sandwich, where the gel is 
allowed to be attached with the nitrocellulose membrane in order to have successful transfer 





The membrane was stained with Ponceau S for 2 mins to visualize total proteins band 
and to confirm successful transfer. Following, the membrane was cut according to the 
molecular weight of the proteins of interest and subjected to blocking in 5% skim 
milk buffer for 1 hour at room temperature. This step is important to prevent 
unspecific binding of antibodies to other bindings sites on the membrane. Primary 
incubation of membranes were performed overnight at 4°C on a shaker with 
corresponding primary antibodies diluted in 5% skim milk TBS-T (Table 3.5). 
Membranes were washed 3 x 10 mins in TBS-Tween washing Buffer before adding 
Horseradish Peroxidase (HRP) conjugated secondary antibody of the host species of 
primary antibody for 1 hour at room temperature on a shaker. All the secondary 
antibodies (Table 3.5) were diluted in blocking buffer.  
 
Table 3.5 Primary and Secondary Antibodies used for immunoblotting  
 
Prior to detection of proteins, the membranes were washed 3 x 10 mins to get rid of 
unbound secondary antibodies. The visualizing was performed using Image Reader 
LAS-3000 (Fujifilm Medical System Inc., Connecticut, USA) and chemiluminescent 
detection kit, either SuperSignalTM West Pico PLUS Chemiluminescent Substrate 
or/and SuperSignalTM West Femto Maximum Sensitivity Substrate (34080, 34096, 
Thermo Fisher Scientific, Waltham, USA. the membranes were developed in 
increment mode at intervals of 10 seconds. Images were analyzed using a combination 
of Multi Gauge software and Image J (USA).  
 
Primary  Supplier Catalogue  MW Dilution Host Buffer 






























5% skim milk TBS-T 
Secondary   Supplier Catalogue  Dilution Buffer 
Antibody    Number       
Goat anti-Mouse IgG (H+L), Invitrogen 31430 1:10000 5% skim milk TBS-T 
HRP  USA        
Goat anti-Rabbit IgG (H+L), Invitrogen 31462 1:10000 5% skim milk TBS-T 
HRP  USA        
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3.4 Statistical Analysis  
 
All statistical analyses were performed using GraphPad Prism8.2.1 The realtive band 
intensity significance from immunublotting was analysed by one sample t test and 
Wilcoxon test. P-values less than 0.05 were considered as significant.  
One sample t-test and Wilcoxon test: nsP>0.05, *P<0.05, 
 
3.5 Transmission electron microscopy (TEM)  
TEM was performed to confirm the presence of different EVs and to analyze the 
morphology and size. This technique allows to characterize very small 
objects/particles with 1μm to 1 nm in size. TEM consists of an electron emission 
source, electromagnetic lenses and an electron detector. It is based on a beam of 
highly energetic electrons released by an electron gun that pass through a sample 
within a high vacuum. When the beam passes through, the electrons are absorbed 
differently by different areas of a sample. The sample modifies the beam and imprint 
its conventional image. The electrons are captured from below the sample onto a 








Figure 3.3 Transmission Electron Microscopy (TEM) overview. Left: Electron beam 
pasing through a sample and scattered by the sample. Figure adapted from [80]  Right: 
Crabon coated copper grid used to mount samples on. Figure adapted from [81] 
 
10 μg of EVs protein of the intact EVs resuspended in PBS was dropwise placed on a 
parafilm. With forceps, a formvar carbon coated copper grid with 200 mesh was 
positioned with the coating side facing the drop containing EVs of interest for 15 
mins. 3 drops of PBS was placed on the parafilm, and the grid was washed 
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sequentially on top of each droplets. Absorbing paper was used between every 
washing step. Following, 2,5% glutaraldehyde (25% glutaraldehyde stock solution 
diluted in 0.1 M sodium cacodylate) was placed on the parafilm to post-fix the 
samples. Following 10 mins incubation, the grid was subjected to 5 droplets of 
deionized water for washing. The sample was contrasted by adding the grid on a 
droplet of 2% uranyl acetate and incubating for 10 mins.  Excess liquid was removed 
and grid with the coated side facing up was dried for 5 mins. The prepared grid was 
either examined by TEM or stored in a grid box for later examination.  
The grid was examined with Jeol Jem-1230 transmission electron microscope at 80 
kV, and images captured with MultiScan Camera (Gatan) model 791.  
 
3.6 Mass spectrometry (MS)  
We performed mass spectrometry to check the protein composition in the EVs, 
commonly EV- associated proteins and to show if the abundance/expression of these 
proteins is different in treated vs. untreated vesicles. The principle behind MS and 
how the data is interpreted in the MaxQuant proteomic software is to be found in 
Appendix I.  
 
3.7 Vesicle Transfer Assay  
3.7.1 Labeling of exosomes with PKH67  
 
The PKH67 Green Fluorescent Cell Linker Kit (Sigma-Aldrich, USA) consisting of 
diluent C and PKH67 dye was prepared in such a way ending up with 4 x 10-6 M 
PKH67 dye. The samples were prepared by taking out 25 µL (equivalent to 25 µg) of 
exosomes resuspended in PBS and 25 µl PBS which act as control without exosomes. 
Diluent C was added to exosomes and control to a total volume of 1 mL. Following, 
the exosomes/diluent C mixture was added to dye/diluent C mixture and incubated for 
5 minutes with periodically intermittent pipetting. 1% BSA was added to the samples 
and control in order to prevent unwanted binding of the dye. Later, the PKH67 stained 
exosomes and ctrl were transferred to PBS pre-wet 300kDa filter (Vivaspin filters). 
Filters containing the samples were centrifuged at 4000 x g in short periods to make 
sure a small part of the sample was remaining on the top. Samples were then washed 
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twice with PBS at 4000 x g and transferred to new pre-wet 300 kDa filters. Exo dep. 
DMEM was added and a last centrifugation step was performed to complete the 
staining of the exosomes.  
24 hrs. prior to exosome staining, 5.0 x 10 4 cells were seeded in a 6-well plate. A 
coverslip was placed in every well, and the cell suspension was carefully added so the 
cells were allowed to adhere on the surface of the coverslip for 24 hrs. The stained 
exosomes and control was added to respective wells and incubated at 37 ° C for 24 
and 48 hrs. 
3.7.2 Cell fixation with Paraformaldehyde (PFA) 
 
Before visualizing the uptake kinetics with microscope, the cells were fixed 24 and 48 
hrs. post exosome incubation. The old media from the 6-well plate was aspirated and 
washed with PBS twice. Following, the cells were incubated with 4 % PFA for 15 
mins at room temperature to allow fixation. Then washed with PBS and subsequent 
with water to rinse of PBS in order to avoid formation of crystals. The coverslips were 
gently placed on a slide containing a droplet of Vetashiled mounting medium. The 
slides were allowed to dry overnight at RT.  
 
3.7.3 Confocal microscopy  
The uptake of the exosomes into the GBM cells was visualized by Leica TCS SP8 
STED (stimulation emission depleted) 3X confocal microcopy. In principal, confocal 
microscope uses fluorescence optics, where the laser light focused onto a define spot 
resulting in emission of fluorescent light only from that particular area. A light 
detector will only sense fluorescence signal from the illuminated spot, while a pinhole 
blocks any other scattered light emitting from the sample. Raster scanning pattern of a 
specimen creates images with one single optical plane [82].  
Leica TCS SP8 STED provides with super-resolution that allows to visualize structure 
smaller than ~ 200 nm. It matches the wavelength of any fluorophore and allows for 
up to eight excitation lines usage simultaneously with its white light laser source. But, 
the peak excitation wavelength and the emission wavelength of two different proteins 
must be separated by 50-60 nm in order to be sensed by two distinct fluorescent 




3.8 WST-1 Cytotoxicity Assay  
We wanted to investigate if TK. mRNA or protein and GCVp, GCVpp or GCVppp 
could induce any potential cytotoxicity onto naïve U87 by traveling through EVs. We 
approach this by performing WST-1 assay which is a technique used to measure cell 
proliferation and viability.  Water soluble tetrazolium (WST) salts are produced by 
adding positive or negative charges and hydroxy groups to phenyl ring of the 
tetrazolium salt. WST-1 (Cell Proliferation Reagent WST-1, 11644807001, Roche, 
Mannheim, Germany) is not able to pass through the cell membrane due to its 
negative charge. Mitochondrial dehydrogenase acts as an intermediate electron 
acceptor and transfer electrons from the plasma membrane to cytoplasm for the 
reduction of tetrazolium into a soluble formazan dye. Only the viable cells are able to 
reduce tetrazolium to formazan, so the amount of formazan produced correlates with 









Figure 3.6 Tetrazolium salt WST-1 cleaved to formazan. Cellular enzymes cleave the 
tetrazolium salt into formazan, and the amount of formazan dye produced correlates with the 
number of viable cells in the culture. Figure is adapted from Cell proliferation Reagent WST-










U87 cells were washed, trypsinized and seeded in 96-well plates in a density of 1.5 x 
104 cells/100 µL exo dep. DMEM in 5 replicates. The set up for potential cytotoxicity 
by TK. mRNA or the protein is shown in table3.6. 8 hrs. post-seeding, a final GCV 
concentration of 25 µM was added to the specific wells. After 96 hrs., an el-pipette 
was used to achieve precise addition of 7µL WST in each well and incubated for 1 hr., 
before scanning the plate by spectrophotometer.   
 

























1 U87 -  -  -  
2 U87 -  25  µM -  
3 U87 U87.TK -  -  





4.1 Analysis of EV secretion in glioma cells 
U87, a widely used human glioma cell line [85] is known to secrete EVs [67] . First, 
we needed to confirm EV secretion in our model system where we used U87 cells that 
previously have been modified by lentiviral vectors in our laboratory to express TK-
GFP (hereafter designated as U87.TK). To investigate the secretion and confirm 
successful harvest of EVs, U87 and U87.TK cells were grown as adherent monolayers 
cultured in exosome depleted culture medium as described in the methods section. 
Isolated EVs were subjected to immunoblotting by using antibodies against the 
tetrapanins CD9, CD63 and CD81 which serve as markers for both exosomes and 
MVs.  Enrichment of these proteins in both exosomes and MVs is known to be highly 
dependent on the parental cell type [69]. CD81 showed the most consistent 
enrichment in exosomes and MVs and was therefore selected to be further used for 
the detection of exosomes and MVs in this project (figure 4.1). Calnexin, an integral 
protein derived from the endoplasmatic reticulum (ER), was used as a negative 
control for MVs and exosomes, but was found to be present in the ApoBDs. ApoBDs 
are known to be larger vesicles than the two other EVs subtypes based on size and 
more likely to incorporate a larger amount of RNA/protein or organelles. The absence 
of calnexin in other lanes indicate that MVs and exosomes did not contain ER 
contaminants.  
 
To further confirm the enrichment of CD81 in the exosomes and MVs we used P3 cells 
which are human stem-like glioma cells cultured in serum-free neurobasal medium. We 
observed enrichment of CD81 in exosomes and MVs harvested from P3 and TK-
modified P3 cells (designated as P3.TK) (Figure 4.2). Thus, the secretion and successful 
harvest of the exosomes and MVs was confirmed in two different glioma cell lines.  
 Figure 4.1 Characterization of EVs from U87/U87.TK and P3/P3.TK cells by immunoblotting. The 
presence of EVs in two different glioma cell lines, U87/U87.TK and P3/P3.TK were confirmed by 
immunoblotting. CD81, an exosomal enrichment marker was found to be present in exosomes and MVs 
confirming successful secretion of these EVs. The blot is representation of 3 individual experiments. ApoBDs – 
Apoptotic Bodies,  MVs – Microvesicles, Exo –Exosomes.  
43 
 
While immunoblotting confirmed successful secretion of EVs in our model system, we 
further performed microscopic analyses using Transmission electron microscopy 
(TEM) to validate these observations.  Figure 4.2 A, B and C shows the images obtained 
from EVs secreted from U87 and U87.TK. The EVs were abundant and appeared to be 
of typical cup-shaped structure. ApoBDs are known to have size that ranges between 
500 nm to 5000 nm [86]. In our experimental setting, we observed larger vesicles in 
GCV treated U87.TK cells corresponding to ApoBDs, however, we found smaller 
vesicles of size similar to exosomes and MVs in U87 WT and U87 TK ApoBDs 
fractions. This suggests that the pelleting of ApoBDs at 2000 x g centrifugal speed is 
also pelleting exosomes-like vesicles along with ApoBDs, indicating exosomal 
contaminants in ApoBDs fractions. In all isolates from the three different cell types, 
MVs and exosomes showed cup-shaped lipid bilayer membrane structures and sizes 
similar to the ones previously reported by other research groups [87] [86]. This 
demonstrates that the presence of EVs in the culture media of U87 and U87.TK cells 












4.2. Analysis of EVs from GBM cells by Transmission electron microscopy. Micrographs of vesicles, 
negatively stained, released from three different cell lines; U87 WT, U87.TK and U87.TK+GCV are 
shown. A-panel shows exosomes vesicles that are cup shaped and have diameter between 40-120nm. B-
panel displayed MVs that have sizes between 100nm to 250nm and were diverse in shape and density. 
C-panel displayed fractions of ApoBDs that were pelleted at 2000 x g showed exosomes like vesicles 
that were pelleted with ApoBDs with a size ranges between 80-400nm in our experiments. Scale bar:  
Exosomes – 100nm, MVs – 200nm and ApoBDs – 300nm. (n=3) ApoBDs – Apoptotic Bodies, MVs – 
Microvesicles, Exo –Exosomes.  
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4.2. The Effect of GCV-mediated cell death on the secretion of exosomes and MVs 
in GBM cells  
To unravel the involvement of ApoBDs, MVs and exosomes in the bystander effect 
during TK/GCV therapy in GBM cells, it is important to identify the effect of GCV-
mediated cell death on the secretion of EVs. First, we performed mass spectrometry 
with extensive analysis of the proteome where we identified more than 1500 different 
proteins in all samples (Table 4.1). Based on a heat map with supervised clustering 
(see Appendix II, figure 4.10) we identified two large separate clusters, with cell 
lysates in one group, whereas EVs clustered together in a separate group. We also 
identified a modest increase of proteins in samples treated with GCV (see Appendix 
II, Figure 4.11).  
Table 4.1- Total identified proteins 
Sample Type Total identified proteins  
TK Exosomes   1662 
TK Exosomes + GCV  1925 
TK MVs  1528 
TK MVs + GCV  1713 
TK ApoBDs 2248 
TK ApoBDs + GCV  2544 
TK Cell lysate  1963 
TK Cell lysate + GCV  2326 
 
Next, we wanted to identify if there were any differences in enrichment of proteins 
that are normally presented in EVs such as CD9, CD81 and TSG101. In the heatmap 
(Figure 4.3), the different types of EVs clustered together which was independent of 
the treatment. However, we also identified differences in the expression of specific 
proteins following GCV treatment. We observed upregulation of CD9 and CD81 in 
GCV-treated exosomes and MVs, while a downregulation of the same proteins was 
found in GCV-treated ApoBDs (Figure 4.4). Determination of relative intensity 
further demonstrated that CD9 and CD81 are more abundant in GCV-treated 
exosomes and MVs, but not in cell lysates indicating that GCV-mediated cell death 














Figure 4.3 Upregulation of key marker proteins of exosomes and MVs:. Mass spectrometry 
analysis revealed that CD81 and CD9 is upregulated in treated exosomes and MVs, while it is 
downregulated in treated ApoBDs  
Figure 4.4 Increased CD81 and CD9 in EVs following GCV treatment. Increase of CD9 and 
CD81 in treated exosomes is clearly observed. The difference in MVs and ApoBDs is modest. 
Included are imputed values from mass spectrometry  








































2. TK + GCV Exo
3. TK MVs
4. TK + GCV MVs
5. TK ApoBDs
6. TK + GCV ApoBDs
7. TK Cell lysate
8. TK+ GCV Cell lysate
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Originally, we planned to further analyze the harvested vesicles by using a particle 
counter (Zeta View Nanoparticle Tracking Analysis, NTA) to assess and quantify the 
amount of secreted EVs with our collaborator at the University of Gothenburg. 
Unfortunately, due to the unexpected events created by the coronavirus outbreak we 
were not able to perform this experiment. Instead, we decided to use semi-quantitative 
immunoblotting with anti-CD81 antibodies on lysates from exosomes and MVs from 
TK. GFP + GCV cells and TK.GFP cells from three independent experiments. (Figure 
4.5 A). CD81 was also detected in ApoBDs fractions, however mostly at a lower level 
compared to other EV subtypes. Interestingly, we observed a trend of increased 
expression of CD81 in EVs from cells treated with GCV versus untreated (UT) cells, 
however the difference was not significant for exosomes and ApoBDs, but for MVs. 




Figure 4.5 Analysis of extent of EVs secretion by using immunoblotting . A. One representative (out of 3) 
experiment. Increased CD81 is detected in the EVs following GCV-treatment. Calnexin is included as a negative 
control for exosomes and MVs . Cell lysates are included as control samples. B. Statistical analysis was performed 
by using One sample t test and Wilcoxon test. The significant increase of CD81 was only confirmed between 





4.3 TK.GFP protein is loaded in the EVs of GBM cells  
As we have shown in the previous sections that EVs are secreted during suicide gene 
therapy, we aimed to investigate whether the secreted EVs contained the TK.GFP 
protein which could potentially contribute to the BE during HSV-TK/GCV therapy. 
GFP is a fusion protein that is not expressed independently from TK. We used both 
immunoblotting and mass spectrometry to detect the presence of TK. 
EVs harvested from U87.TK cells (with or without GCV treatment) and U87.WT 
cells were analyzed by immunoblotting with anti-GFP and anti-CD81 antibodies. The 
molecular weight of HSV.TK is around 40 kDa, but as it is fused to GFP with 
approximately 27 kDa, we anticipated bands at around 70 kDa. GFP is a fusion 
protein that is not expressed independently of TK. As expected, (Figure 4.6), bands 
were observed in the cellular fraction of U87.TK cells but not in U87. CD81 
expression confirmed the presence of exosome and MVs in these fractions. Our result 
indicates that the TK.GFP fusion protein is loaded in the EVs. To further confirm this 







Figure 4.6 Confirmation of TK.GFP in the vesicles by immunoblotting. The presence of 
exosomes, MVs, ApoBDs and cell lysate in U87, U87. TK and U87.TK +GCV is confimed with 
CD81 and Calnexin. Our result indicates that the TK-GFP fusion protein is loaded in the EVs, 
but the expression in U87.TK exosomes are low.  
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Our mass spectrometry data revealed that the HSV-TK and GFP protein is present in 
all fractions secreted from U87.TK cells (Figure 4.7). There was no clear expression 
of the TK.GFP in wild-type U87 cells and their EV subtypes as expected. 
Interestingly, the enrichment of GFP and HSV.TK increases in MVs and ApoBDs 
from GCV treated TK cells, compared to the untreated TK cells. There were no 
significant changes observed between exosomes from both the cell types. The GCV-
treated ApoBDs showed the highest expression of TK. Thus, we demonstrated that the 



















Figure 4.7 Confirmation of HSV.TK and GFP protein in the vesicles by mass spectrometry 
The presence of exosomes, MVs, ApoBDs and cell lysate in U87, U87. TK and U87.TK +GCV 
is confirmed with CD81 and Calnexin. Our results indicate that the TK-GFP fusion protein is 
loaded into the EVs.   










































2. TK + GCV Exo
3. TK MVs
4. TK + GCV MVs
5. TK ApoBDs
6. TK +GCV ApoBDS
7. TK Cell lysate




12. WT Cell lysate
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4.4 Transfer of EVs to other cells  
After confirming that EVs contain the TK-GFP protein as cargo it would be important 
to analyze whether the EVs are capable of transferring the suicide gene product into 
recipient cells.  To study this transfer, we planned to exploit PKH26 dyes that would 
stain the EVs and would discriminate from the cells stained with blue nuclear dye and 
green cytoplasm due to the GFP-tagged TK protein. However, to optimize the 
protocol, we first performed a pilot experiment to analyze if the exosomes are being 
transferred at all. In this pilot experiment, we labelled exosomes with PKH67 green 
dye (ex: 490 nm and em: 502 nm) and the nucleus of the cells with DAPI staining. 
When imaging with confocal microscopy we observed that the blue nucleus of the 
U87 recipient cells were surrounded by small green dots (Figure 4.8). The negative 
control is a PBS/medium control that was included to show the unbound form of dye 
without vesicles that was washed out during filtration. Our results suggest that the 
exosomes are likely transferred to recipient cells, however, we could not verify if the 







Figure 4.8 Exosome transfer assay visualized with confocal microscopy. Panel A & B: Dapi stained 
nucleus surrounded by exosomes stained in green, Panel C: Negative control, shows only cells.  
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4.5 Cytotoxic effect of ApoBDs from TK-positive glioma cells 
As our results indicated that TK could be transferred through secreted vesicles from 
donor to recipient TK-negative cells, we wanted to investigate if the transferred 
protein could induce a potential cytotoxicity on naïve U87 by traveling through EVs. 
The mass spectrometry results (section 4.3) revealed that the abundance of TK protein 
was highest in ApoBDs and therefore we chose to first proceed with this vesicle 
subtype.  
96 hrs post incubation of U87.TK-derived ApoBDs with U87 naïve cells revealed the 
presence of the ApoBDs in the culture medium and the fluorescence emitted green 










After verifying the presence of TK.GFP in the ApoBDs we performed a cytotoxicity 
assay to analyze potential contribution of ApoBDs to the BE through uptake into 
naïve cells. However, we could not identify any significant differences in cell 






Figure 4.9 Cytotoxicity assay with ApoBDs. Left: A. Only U87 naïve cells. B) U87 naïve cells treated 
with GCV after 8 hrs. C) U87 naïve cells treated with ApoBDs loaded with TK protein. D) U87 naïve cells 
treated with ApoBDs containing TK protein and GCV. Right: Ratio of cell viability. Do not observe 





The highly aggressive and invasive nature of GBM limits the outcome of standard 
therapy which involves safe surgical resection, followed by radiotherapy (RT) and 
concomitant chemotherapy with TMZ  [30]. This resistance to conventional 
treatments, which in addition is caused by tumor heterogeneity and a highly 
immunosuppressive microenvironment results in poor survival outcome and high 
mortality rate [31].  
Suicide gene therapy is a promising treatment alternative which converts a nontoxic 
prodrug into a cytotoxic drug that kills dividing tumor cells. It has been shown in 
earlier studies that the metabolized cytotoxic drug spreads to neighboring cells 
through gap junctions to execute BE [53, 54]. While gap junction-mediated BE is 
highly characterized in the HSV-TK/GCV system, it is not properly clear if soluble 
factors such as ApoBDs, MVs and exosomes play any role in this process. In addition 
to the BE mediated by the toxic drug, it is, in theory possible, that mRNA or protein 
of the suicide gene could be transferred from the TK-transduced cells via EVs during 
HSV-TK/GCV suicide gene therapy. In this regard, the involvement of EVs in the 
mechanism of BE has been studied in CD/5FC mediated SGT, which is another 
widely used SGT system.  It has been reported that exosomes produced by CD-
expressing MSCs contain the mRNA transcript of the suicide gene which can cause 
cytotoxicity in neighboring cells [57]. In the TK/GCV system, the involvement of 
ApoBD-mediated BE has been suggested, but not conclusively determined [56]. 
Furthermore, it was not investigated if the ApoBD-mediated BE was caused by the 
transfer of TK mRNA, TK-protein, or the toxic drug [56] . In addition, the 
involvement of exosomes and MVs has not been investigated in the context of 
TK/GCV-mediated SGT. The objective of this thesis was to analyze the potential 
involvement (and mechanism) of EVs in BE of HSV-TK/GCV therapy. 
Hypothetically, an EV-mediated BE can be executed through 3 major routes: 1) 
transfer of TK mRNA that can be translated into active protein in the recipient cells, 
2) transfer of TK protein and 3) transfer of phosphorylated GCV. In this project, our 
major focus was on the potential transfer of the TK protein. We analyzed the presence 
of the TK protein in EVs by using mass spectrometry and immunoblotting and 





We confirmed secretion and successful harvest of EVs in our model system according 
to the MISEV2018 requirements set by ISEV which demand investigation of specific 
proteins to evaluate the purity of the exosome isolate and other EVs [62]. Primary 
antibodies against calnexin, CD81, CD63, flotillin-1, TSG-101 and CD9 have already 
been used previously to demonstrate the presence (or absence in case of 
calnexin/calreticulin) of the EV-associated proteins to confirm the existence of EVs. 
However, the enrichment of marker proteins depends on the parental cell type and 
some EV markers are not always present in all EVs [88]. Our results showed that 
CD81 was abundant in the EVs of U87 and its derivative cells in a consistent manner 
and therefore we selected CD81 as a reliable EV marker protein in this study. We also 
showed that CD81 was enriched in P3/P3.TK, a GBM cell line cultured in serum-free 
medium.  
Even though immunoblotting is a sensitive analysis method, we confirmed the 
presence of EVs with a second method. TEM analysis revealed bilayered-membrane 
vesicles that were cup-shaped and heterogenous in size, which is characteristic for 
EVs. The exosomes and MVs  were found to have a size that correlates with the 
predicted size of the EVs in the literature [58, 63]. Electron microscopy in general 
(TEM or Scanning electron microscope (SEM)), is a standard method for 
characterizing the morphology of particles smaller than 300 nm [89]. Even though the 
method provides us with morphological information such as shape and size, it does 
not allow to fully discriminate between the vesicle subtypes but confirm the presence 
of the EVs. ApoBDs and MVs samples can still be contaminated with exosomes. 
Indeed, our TEM analysis shows that the ApoBDs may have been contaminated with 
other EVs. This issue could have been resolved by using specific markers found to be 
enriched in ApoBDs of some cell types. Example of such marker proteins are 
Annexin V, Thrombospondin and C3b [63] [75].  ApoBDs and MVs samples can still 
be contaminated with exosomes which can explain the size discrepancy observed in 
the images of ApoBDs. However, for precise determination, investigation with 
Nanoparticle Tracking Analysis (NTA) would be necessary.   
Further, to investigate the effects of GCV-treatment on the EVs, we subjected the 
different EV fractions and cell lysates to mass spectrometric analysis. First, we 
identified at least 1300 different proteins with modest increase of proteins in EVs and 
cell lysates treated with GCV. The separate clustering of EVs and cell lysates also 
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confirms the diverse nature of the proteins presented in the EVs and cell lysates. We 
also observed that the exosomes were separately clustered in one group and the rest of 
the EV subtypes in another group.  
Detailed analysis of the mass spectrometry data reveled an upregulation of CD81 and 
CD9 in these EV subtypes upon GCV treatment, suggesting that the extent of 
secretion of exosomes and MVs was increased following TK/GCV treatment. 
Immunoblot analysis showed a trend of similar increase. In line, mass spectrometry 
data showed that more TK and GFP protein is loaded in EVs following GCV 
treatment, which may also indicate the increased extent of EV secretion. In this 
context, it is noteworthy that immunoblot is in general not fully quantitative and thus 
not the best method to investigate extent of secretion of EVs. Furthermore, in our 
experiments, we did not use any loading controls which could be used as a 
normalizing factor. Recent evidence shows the presence of house keeping genes 
including Actin and GAPDH, but they differ in band intensity between the vesicles 
type [90] . Therefore, there is no specific loading control that could define as a house 
keeping gene for EVs. Thus, although our data indicate that TK/GCV therapy 
increases the secretion of exosomes and MVs, further confirmation by using 
quantitative nanoparticle analysis would be absolutely necessary. 
 
After having confirmed that the HSV-TK protein is loaded as a cargo in all vesicle 
fractions, we wanted to determine if the TK protein has enzymatic activity following 
transfer into the recipient cells. As our proteomic results revealed that the ApoBDs 
had the highest amount of TK protein, we proceeded with this EV-subtype to analyze 
the suicide effect on recipient cells. We performed a cell viability assay (WST-1 
assay), where we expected that the recipient naïve cells incubated with TK containing 
ApoBDs would have increased cell death upon treatment with GCV.  However, our 
results did not show any suicide activity. Unfortunately, due to the crisis related to 
COVID-19 and consequent time restrictions, we performed this experiment only once. 
Thus, no major conclusion can be drawn yet. In future more experiments will be 
necessary to verify this observation. It would be also important to optimize the 
experimental protocol. For instance, in our set-up we did not centrifuge the ApoBDs 
after applying them onto naïve cells. Subsequent centrifuge may improve the uptake. 
Thus, in the future the potential uptake may be facilitated by centrifuging the plates 
after addition of ApoBDs in order to make sure that the ApoBDs get incorporated into 
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the recipient cells, and not float in the media without contact to the recipient cells. 
One should also include ApoBDs from U87 wild-type cells as control to get more 
reliable results. It would be important to analyze if the transfer is successful with 
ApoBDs and MVs as well.  
Since exosomes and MVs from the TK positive cells also contain the TK protein it 
will be important to investigate the potential transfer and cytotoxicity of these 
fractions by using WST assay in a similar manner as for ApoBDs in future. In this 
regard, we have observed that the exosomes surround the nuclei of recipient cells, 
suggesting that the U87 cells may be susceptible for uptake of exosomes. More 
advanced microscopy will be needed to confirm if the vesicles are on top or inside the 
recipient cells.    
In the future it will be important to verify all results in an additional cell line and most 
preferably in the P3/P3 TK cell line. The P3 cell line is a patient-derived GBM cell 
line cultured in serum-free media which is more relevant to the clinical scenario [91]  
In the future, it will also be important to analyze if the TK mRNA can be loaded into 
the EVs and if so, one should investigate if this mRNA eventually can be transferred 
into the recipient cells and translated into protein. One possible way to analyze if the 
mRNA is loaded in the EVs is to perform quantitative reverse transcriptase PCR 
(qPCR) by using primers against the TK.GFP transgene. Furthermore, it should be 
investigated whether the metabolized toxic GCV-DP/TP could contribute to BE by 
traveling through EVs. This could be approached by mass spectrometry to reveal the 
abundance of GCV-DP/TP in EVs. Thereby, the abundance of GCV-DP/TP in the 
different EV subtypes could be determined as well and we could identify specific EV 
subtypes with a potentially high BE. Indeed, we planned to carry out this experiment. 
However, the proteomics facility at the University of Bergen has not the equipment 
and expertise for such analysis. We contacted the proteomics facility at the Norges 
teknisk-naturvitenskapelige universitet (NTNU) who could perform this analysis, but 
since they do not prioritize external projects, it was not possible to receive results in 
time.  
 
It is noteworthy to mention that several important experiments of this thesis could not 
be pursued due to the Covid19-related crisis. The first major experiment or analysis 
that was hindered and finally cancelled by this crisis was Nanoparticle Tracking 
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Analysis (NTA). This method allows for determination of both size distribution and 
relative concentration of EVs in a sample and is the most reliable method for 
quantification of EVs [92]. The NTA was supposed to be performed with the help of 
our collaborator at the University of Gothenburg. This method would have been a key 
method to reliably quantify all EV fractions in most of the experiments of this thesis.  
Thus, many of our quantitative results, specially from the immunoblots, in this thesis 
need to be interpreted with caution.   
Practically, we lost more than 1,5 months due to the crisis. The limited time did not 
allow us to perform cytotoxicity assays with exosomes and MVs, and also hindered us 
from pursuing further cytotoxicity experiments with ApoBDs with a modified 
protocol. Because of the unexpected results with the ApoBDs it was highly important 
for us to check transfer of ApoBDs into recipient cells. In the future this could be 
analyzed with two independent methods such as high-resolution microscopy and flow 
cytometry.  
In the future it will be interesting to perform an inhibition experiment of exosomes 
and MVs. By inhibiting secretion of exosomes by GW4869 drug and MVs production 
by ROCK inhibitor it could be possible to confirm the involvement of EVs in the 
contribution of HSV-TK/GCV-mediated BE.  
 
Conclusion  
Our major finding and main observation from this thesis is the presence of the 
TK.GFP protein in ApoBDs, MVs and exosomes derived from TK-containing tumor 
cells cells. We show that the TK protein can be loaded into the EVs of U87 cells that 
express TK. Our data also suggest that there is an increase in EV-secretion following 
HSV-TK/GCV gene therapy which could, in theory, contribute to BE. However, we 











Heat Denaturation Digestion Protocol  
Heat digestion: 
Add 10 – 20 µl buffer and incubate at RT in Eppendorf mixer for 5 min (slow 
agitation).  
Reduction 
Add 2 -4 µl 100 mM DTT to achieve a 10 mM DTT solution.  
Heat 
Heat sample for 6 min at 95C˚ in and Eppendorf mixer. Let sample cool down to 
room temperature. 
Alkylation  
Add 3 – 6 µl 200 mM IAA for cystein alkylation, and incubate for 1h at RT in the 
dark  
(Note: Iodoacetamide is unstable and light-sensitive. Prepare solutions immediately 
before use and perform alkylation in the dark. If iodoacetamide is present in limiting 
quantities and at a slightly alkaline pH, cysteine modification will be the exclusive 
reaction. Excess iodoacetamide or non-buffered iodoacetamide reagent can also 
alkylate amines (lysine, N-termini), thioethers (methionine), imidazoles (histidine) and 
carboxylates (aspartate, glutamate)). 
To avoid unwanted protease alkylation, add 0.9 – 1.8 µl 100 mM DTT, and incubate 
10 min. at room temperature. 
Buffer: 50 mM Tris/1mM CaCl2: Add 0.61g Tris (art. no. 252859, Sigma-Aldrich) and 
15mg CaCl2 x 2H2O (art. no. 21097, Sigma-Aldrich, stabilize trypsin) to about 90ml 
dH2O. Correct the pH to 7.8-8 with HCl and adjust the volume to 100ml. Store the 
solution at 4 ◦C. 
100 mM DTT in MillQ water: Add 15.4 mg DTT (DiThioThreitol, art. no. D-9163, 
Sigma-Aldrich) to 1ml dH2O. (1M solution (154 mg/ml) may be aliquoted, and kept in 
freezer).  
200 mM IAA in MilliQ water: Add 18.5 mg IAA (Iodoacetamide, art. no. I-6125, 








Oasis protocol (C18 cleanup) 
General notes: Method to de-salt and clean up sample after protein digestion from 
various digestion methods i.e filter aided sample preparation (FASP), in gel and in 
solution digestion. Some sample fractionation methods does not require C18 cleanup. 
Equipment needed:  
- Oasis 96 well cartridge plate 
- 96 well waste plate 
- 96 well elution plate 
- Used Oasis 96 well cartridge and elution plate for balance when centrifuging. 
- Appropriate centrifuge for plates 
- Acetonitrile, Foric acid, Trifluoroacetic acid, MQ water. 
- Pipettes 
NB!  Your sample should not be added before step 5.  Make sure that the solutions 
you add to the cartridge flows through. If not, the cartridge could be damaged, change 
cartridge. If you want to measure protein concentration on Nanodrop after Oasis, 
make sure step 9 and 10 is done with FA and not TFA. 
 
1. Place Oasis 96 well cartridge plate into waste plate.  
 
2. Activate cartridges by adding 500 μL 80% ACN, 0.1% FA. 200 x g - 1 min.  
Discard flow trough 
 
3. Wash cartridges by adding 500 μL 0.1% TFA. 200 x g – 1 min. Discard flow 
trough 
 
4.  Repeat step 3 by adding 500 μL 0.1% TFA. 200 x g – 1 min. Discard flow 
trough  
 
5.  Addition of 300 μL sample. 150 x g – 3 min. Discard flow trough  
 
6.  Wash by adding 500 μL 0.1% TFA. 200 x g – 1 min. Discard flow trough  
 
7.  Wash by adding 500 μL 0.1% TFA. 200 x g – 1 min. Discard flow trough  
 
8.  Wash by adding 500 μL 0.1% TFA. 200 x g – 1 min. Discard flow trough  
 
9.  Elute sample in 96 well elution plate. 100 μL 80% ACN, 0.1% FA. 200 x g – 
1 min. KEEP FLOW THROUGH!  
 
10. Elute sample in 96 well elution plate. 100 μL 80% ACN, 0.1% FA. 200 x g – 1 
min KEEP FLOW THROUGH! 
 
11. Dry the samples in SpeedVac. To speed up the process put samples in - 80˚C 
for 15 minutes. 
 





NanoLC-ESI- QExcative HF mass spectrometry at PROBE 
About 0.5ug protein as tryptic peptides dissolved in 2% acetonitrile (ACN), 0.5% 
formic acid (FA), were injected into an Ultimate 3000 RSLC system (Thermo 
Scientific, Sunnyvale, California, USA) connected online to a Q-Excative HF mass 
spectrometer (Thermo Scientific, Bremen, Germany) equipped with EASY-spray 
nano-electrospray ion source source (Thermo Scientific). 
Trapping and desalting 
The sample was loaded and desalted on a pre-column (Acclaim PepMap 100, 2cm x 
75µm ID nanoViper column, packed with 3µm C18 beads) at a flow rate of 5µl/min 
for 5 min with 0.1% TFA. 
LC RUN (195 min) 
Peptides were separated during a biphasic ACN gradient from two nanoflow UPLC 
pumps (flow rate of 250 nl/min) on a 25 cm analytical column (PepMap RSLC, 50cm 
x 75 µm ID  EASY-spray column, packed with 2µm C18 beads). Solvent A and B 
were 0.1% FA (vol/vol) in water and 100% ACN respectively. The gradient 
composition was 5%B during trapping (5min) followed by 5-7%B over 0.5min, 7–
22%B for the next 61.0min, 24-35%B over 23 min, and 35–90%B over 5min. Elution 
of very hydrophobic peptides and conditioning of the column were performed during 
3 minutes isocratic elution with 90%B and 15 minutes isocratic conditioning with 
5%B. 
(a simplified elution gradient annotation – “Ret.time(%B)”: 0(5) – 5(5) – 5.5(7) – 
65(22) – 87(35) – 92(80) – 102(80) – 105(5) – 120(5) 
 
DDA, Q-Excative HF 
The eluting peptides from the LC-column were ionized in the electrospray and 
analyzed by the Q-Excative HF. The mass spectrometer was operated in the DDA-
mode (data-dependent-acquisition) to automatically switch between full scan MS and 
MS/MS acquisition. Instrument control was through Q Excative HF Tune 2.8 and 
Xcalibur 3.1 
Survey full scan MS spectra (from m/z 375-1500) were acquired in the Orbitrap with 
resolution R = 120 000 at m/z 200, automatic gain control (AGC) target of 3e6 and a 
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maximum injection time (IT) of 100ms. The 12 most intense eluting peptides above 
an intensity threshold of 50 000 counts, and charge states 2 to 6, were sequentially 
isolated to a target value (AGC) of 1e5 and a maximum IT of 110ms in the C-trap, 
and isolation width maintained at 1.6 m/z (offset of 0.3 m/z), before fragmentation in 
the HCD (Higher-Energy Collision Dissociation) cell. Fragmentation was performed 
with a normalized collision energy (NCE) of 28 %, and fragments were detected in 
the Orbitrap at a resolution of 15 000 at m/z 200, with first mass fixed at m/z 100.  
One MS/MS spectrum of a precursor mass was allowed before dynamic exclusion for 
20s with “exclude isotopes” on. Lock-mass internal calibration (m/z 445.12003) was 
enabled. 
Ionsource parameter 
The spray and ion-source parameters were as follows. Ion spray voltage = 1800V, no 




Add 55 – 110 µl buffer (the urea concentration is now reduced to 1M). 
Trypsinaddition for proteolysis 
Add trypsin in amount about 50 times lower than the amount of protein in the sample. 
If the sample contains approx. Ex 100 µg protein, add 2µg of protease a 0.5 µg/µl . 
Check pH with a litmus paper. pH needs to be neutral/around 7 to 8. Incubate samples 
at 37 ˚C overnight (16h) on a thermo-shaker or in a heat cabinet. 
Stock of trypsin a 0.5 µg/µl  (Promega, art. no. V 5111);  
Dissolve one ampoule (20 µg trypsin porcine powder) in 40 µl Promega resuspension 
buffer (50 mM HAc).  
To make aliquots of Trypsin Porcine a 1µg per 10µl (Promega, art. no. V 5111) 
Dissolve one ampoule (20 µg trypsin porcine powder) in 200 µl 50 mM acetic acid 
(resuspension buffer supplied from Promega). The trypsin concentration in this stock 
solution is then 0.1 µg/µl.  
Aliquot a 10µl may be frozen at -20 ˚C for 1-2 months in aliquots. Trypsin stock 
solution may be diluted in buffer before use. 
Acidification  
In this final step, acidify with 10% TFA (trifluoroacetic acid) to a 0.5-1% final 
concentration of TFA (check with a litmus paper). Add 150-200 µl 0.1% TFA to 







Figure 4.10 Heatmap representing supervised clustering. Blue represents downregulated proteins, while 
red represents upregulated proteins. Data represent one experiment. The samples cluster in two main groups, 









Figure 4.11 Upregulation of proteins due to GCV-treatment. The four venn diagrams represents the 
proteins found in exosomes, MVs, ApoBDS and cell lysates. We observed upregulation of proteins in GCV 
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